[
    [
        {
            "time": "",
            "original_text": "东莞证券维持泰格医药推荐评级，2021年一季报点评，近期获6份券商研报关注，目标均价涨幅23.46%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "推荐评级",
                    "2021年一季报",
                    "券商研报",
                    "目标均价涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "东莞证券维持泰格医药推荐评级，2021年一季报点评，近期获6份券商研报关注，目标均价涨幅23.46%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "2020年年报",
                    "2021年一季报",
                    "Q1业绩复苏",
                    "CXO",
                    "疫苗",
                    "创新器械",
                    "服务"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2020年年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本概念股多数走软，健康元、泰格医药、金域医学、甘李药业跌幅居前",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "概念股",
                    "走软",
                    "健康元",
                    "泰格医药",
                    "金域医学",
                    "甘李药业",
                    "跌幅"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴资本概念股多数走软，健康元、泰格医药、金域医学、甘李药业跌幅居前",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "杨见松博士：创新药研发的两大瓶颈：转化医学与早期临床开发",
            "features": {
                "keywords": [
                    "杨见松博士",
                    "创新药研发",
                    "瓶颈",
                    "转化医学",
                    "早期临床开发"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "杨见松博士：创新药研发的两大瓶颈：转化医学与早期临床开发",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "东莞证券：泰格医药（300347.SZ）2021Q1业绩同比大增，维持“推荐”评级",
            "features": {
                "keywords": [
                    "东莞证券",
                    "泰格医药",
                    "2021Q1",
                    "业绩同比大增",
                    "推荐评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "东莞证券：泰格医药（300347.SZ）2021Q1业绩同比大增，维持“推荐”评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]